Starlight Cardiovascular is structured around development of much needed tools and devices to treat pediatric Congenital Heart Defects (CHDs). It is estimated that annually some 1.3 million babies are born with this condition. However, most of the tools used to treat these children were designed for adult conditions and anatomy and their use for pediatric patients is limited. To address this deficit, Cardiovascular is developing a portfolio of devices designed and tested specifically for pediatric CHD with the goals of improving morbidity, mortality, and access to care.